Manufacturers Capture Obesity Patient Funnel
Foundation Health
Drug makers are trying to own the patient acquisition funnel for obesity, and telehealth partners are the fastest way to do it without building a national care network from scratch. LillyDirect shows the playbook. Lilly supplies the branded drug, pharmacy routing, and cash pay access, while independent virtual clinics handle screening, prescribing, titration, and follow up. That turns obesity treatment into a guided checkout flow instead of a fragmented doctor, pharmacy, and insurance hunt.
-
This model fits GLP-1s because obesity treatment is not a one time prescription. Programs need intake, labs, dose adjustments, side effect monitoring, and regular messaging. That is why telehealth companies with built in clinicians, diagnostics, and pharmacy workflows are structurally better partners than simple referral sites.
-
The value split is clear in practice. The manufacturer wins branded demand capture and direct cash pay distribution. The telehealth partner wins subscription revenue, visit fees, and pharmacy margin by staying the front door for ongoing care. Ro built a large GLP-1 business this way, with over 50% of its GLP-1 volume flowing through manufacturer direct channels by mid 2025.
-
For Foundation, the strategic opening is that pharma does not need another consumer brand, it needs a behind the scenes operator that can stand up 50 state clinician coverage, prescription routing, fulfillment, and diagnostics quickly. Foundation already sells that infrastructure layer, which is closer to the hard part of launching obesity programs than marketing is.
The next phase is more manufacturer curated care networks tied to branded self pay channels, tighter rules on compounded alternatives, and more pressure on telehealth providers to prove they improve adherence and outcomes, not just access. Companies that can package clinicians, labs, pharmacy, and chronic care workflows into one API layer will be best positioned to power that shift.